Fumiya Sugino
Papers
2
Total Citations
14
H-Index
2
About
Dr. Fumiya Sugino is a dedicated urologic oncologist whose research focuses on advancing treatment strategies for high-risk and very-high-risk prostate cancer. His work centers on optimizing perioperative therapies, particularly through the integration of chemohormonal regimens before radical prostatectomy. Dr. Sugino’s major contributions include demonstrating the efficacy and safety of neoadjuvant luteinizing hormone-releasing hormone (LHRH) antagonists combined with tegafur-uracil (UFT) therapy, a novel chemohormonal approach designed to improve outcomes in patients with aggressive disease. His landmark 2023 study on biochemical recurrence after chemohormonal therapy followed by robot-assisted radical prostatectomy in very-high-risk patients, which has garnered 9 citations, provides critical evidence that this multimodal strategy can delay disease progression. By evaluating both oncologic control and treatment tolerability, Dr. Sugino’s retrospective cohort analyses offer valuable clinical insights for managing a challenging patient population. His work underscores the potential of neoadjuvant strategies to enhance surgical outcomes and reduce recurrence risks, marking him as an emerging contributor to the field of prostate cancer therapeutics.
Research Focus
Key Achievements
Top Papers
- 1
- 2